77901-52-1

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-methoxy-6-nitrobenzoate is used as a key intermediate in the synthesis of various drugs. Its unique chemical structure allows for the development of new pharmaceutical compounds with potential therapeutic applications.
Used in Dye Industry:
In the dye industry, Methyl 2-methoxy-6-nitrobenzoate serves as an important intermediate for the production of dyes with specific color properties. Its chemical structure contributes to the creation of dyes with desired characteristics for various applications.
Used in Perfume Industry:
Methyl 2-methoxy-6-nitrobenzoate is utilized as a precursor in the synthesis of perfumes, where its chemical properties contribute to the development of unique and complex fragrances.
Used in Research Laboratories:
Methyl 2-methoxy-6-nitrobenzoate is employed as a reagent in organic synthesis research, enabling the exploration of new chemical reactions and the development of novel organic compounds.
Safety Note:
Methyl 2-methoxy-6-nitrobenzoate should be handled with care due to its potential harmful effects if ingested or inhaled. Proper safety measures and precautions should be taken during its use in various applications.

InChI:InChI=1/C9H9NO5/c1-14-7-5-3-4-6(10(12)13)8(7)9(11)15-2/h3-5H,1-2H3

Upstream product

• 186581-53-3 diazomethane 
• 53967-73-0 2-nitro-6-methoxybenzoic acid 
• 42087-82-1 methyl 2,6-dinitrobenzoate 
• 124-41-4 sodium methylate 
• 606-20-2 2,6-dinitrotoluene 
• 603-12-3 2,6-dinitrobenzoic acid 
• 4837-88-1 6-methoxy-2-nitrotoluene 
• 75-65-0 tert-butyl alcohol 
• 74-88-4 methyl iodide 
• 5460-31-1 3-nitro-o-cresol 

Downstream Products

• 98488-49-4 2-methoxy-6-nitro-benzoic acid hydrazide 
• 54166-96-0 methyl 2-amino-6-methoxybenzoate 
• 53600-33-2 6-methoxyanthranilic acid 
• 101352-42-5 N,N'-bis-(2-methoxy-6-nitro-benzoyl)-hydrazine 
• 123102-32-9 methyl 2-amino-6-ethyl benzoate 
• 697801-52-8 5-methoxy-4,4-dimethyl-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one 
• 697801-53-9 5-hydroxy-4,4-dimethyl-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one 

Relevant academic research and scientific papers

Aryl Substituted Benzimidazolones as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors

Since the discovery of HIV as the etiological agent of AIDS, the virus has infected millions of people each year. Fortunately, with the use of HAART, viremia can be suppressed to below detectable levels in the infected individuals, which significantly improves their quality of life and prevents the onset of AIDS. However, HAART is not curative and issues relating to adherence and drug resistance may lead to the re-emergence of viremia, the development of AIDS, and ultimately death. To address a pressing need for the development of new and efficacious antiretroviral agents with activity against viruses bearing prevalent resistant mutations, we have designed two generations of benzimidazolone derivatives as HIV non-nucleoside reverse transcriptase inhibitors. The first generation benzimidazolone inhibitors were found to be potent inhibitors of wild-type HIV reverse transcriptase but were ineffective in the presence of common resistance mutations such as K103N and Y181C. A second generation benzimidazolone inhibitor (compound 42) not only showed inhibitory activity against wild-type HIV but also remained active against HIV containing the K103N, Y181C, and K103N/Y181C drug resistance mutations.

Non-nucleoside reverse transcriptase inhibitors

Compounds represented by formula I: wherein R1 is H, halogen, (C1-4)alkyl, O(C1-4)alkyl, and haloalkyl; R2 is H or (C1-4)alkyl; R3 is H or (C1-4)alkyl; R4 is (C1-4)alkyl, (C1-4)alkyl(C3-7)cycloalkyl, or (C3-7)cycloalkyl; and Q is a fused phenyl-5 or 6-membered saturated heterocycle having one to two heteroatoms selected from O and N, said Q being optionally substituted with hydroxy, or (C1-4)alkyl which in turn maybe optionally substituted with pyridinyl-N-oxide or C(O)OR wherein R is H or (C1-4)alkyl; or a salt thereof. The compounds have inhibitory activity against Wild Type, and single and double mutants strains, of HIV.

An Improved Synthesis of 6-Methoxyanthranilic Acid

6-Methoxyanthranilic acid (1) is prepared in three steps from 2,6-dinitrobenzoic acid (6) in an overall yield of 46percent.